Miles White: Reformulating AbbottRichard Melcher
Abbott Laboratories CEO Miles White had to resort to tea and honey after losing his voice, but that barely slowed him down as he went about selling Abbott's $7.3 billion acquisition of ALZA to investors. Early signs were that Wall Street was somewhat hesitant about the price paid for the deal, designed to bolster the $12.5 billion company's drug pipeline with new oncology, urology, and drug-delivery products. "I'm not yet sure ALZA was the right move to make," says SG Cowen analyst Michael Mullen.
Still, the deal, announced June 21, showed that the maker of antibiotics, infant formula, diagnostic gear, and AIDS drugs is stirring after White, 44, succeeded Duane Burnham early this year. The ex-McKinsey consultant joined Abbott in 1984 and headed Abbott's diagnostics unit, where he engineered the 1996 acquisition of MediSense. White insists the ALZA deal will boost Abbott's lagging earnings within a year. And, he says, more deals are ahead: "There are a lot of things I'd like to strengthen." Including his voice, of course.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- ‘No Cash’ Signs Everywhere Has Sweden Worried It’s Gone Too Far
- Morgan Stanley Says Stock Slide Was Appetizer for Real Deal
- Dollar Rises With Treasury Yields; Stocks Struggle: Markets Wrap
- Boom Turns to Bust for Millennials Across Advanced Economies
- How One of the Most Profitable Trades of the Last Few Years Blew Up in a Single Day